No Data
No Data
Beijing Aosaikang Pharmaceutical (002755.SZ) net income in the third quarter increased by 296.25% year-on-year.
Galaxy10 reported on October 30th that Beijing Aosaikang Pharmaceutical (002755.SZ) released its third-quarter report. The company achieved revenue of 1.384 billion yuan in the first three quarters, a year-on-year increase of 23.64%; net income of 0.127 billion yuan, a year-on-year increase of 168.79%. In the third quarter alone, revenue reached 0.462 billion yuan, a year-on-year increase of 13.23%; net income was 51.4232 million yuan, a year-on-year increase of 296.25%.
Express News | Beijing Aosaikang Pharmaceutical: Subsidiary Nalatrexone Malate Tablets Obtained Pharmaceutical Registration Certificate
Express News | Beijing Aosaikang Pharmaceutical: plans to increase capital to AskGene by 0.22 billion yuan
Hong Kong stocks anomaly | Innovent Bio (01801) fell another 10% during the day, reaching a strategic cooperation with Beijing Aosaikang Pharmaceutical, the founder recently reduced holdings by over 0.15 billion Hong Kong dollars of stocks
Innovent Bio (01801) fell by another 10% during the day, as of the time of publication, a decrease of 4.92%, closing at HKD 47.35, with a turnover of 1.627 billion Hong Kong dollars.
Innovent Bio (01801.HK) and Beijing Aosaikang Pharmaceutical have reached a strategic cooperation on the lung cancer targeted drug Aiyixin.
Innovent Bio (01801.HK) and Beijing Aosaikang Pharmaceutical (002755.SZ) recently signed a cooperation agreement. The two parties will achieve exclusive commercial cooperation on the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted drug "Icotinib Tablet" (commodity name: Oyi Xin). Beijing Aosaikang Pharmaceutical will be the holder of the marketing authorization for the collaborative product, responsible for the commercial production and supply of the collaborative product, and will pay Innovent Bio sales and marketing service fees according to the cooperation agreement. Innovent Bio will obtain the exclusive promotion and sales rights of the collaborative product in China mainland, and will pay according to the cooperation agreement
Innovent Bio and Beijing Aosaikang Pharmaceutical have reached a strategic cooperation on the third-generation EGFR TKI lung cancer targeted drug, Elunate tablets (Aoyixin).
On October 8, 2024, in San Francisco, USA, and Suzhou, China / PRNewswire / - On September 30, 2024, Innovent Bio (Hong Kong Stock Exchange stock code: 01801), a biopharmaceutical company dedicated to the research, development, production, and sales of innovative drugs in the major disease areas of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, etc., signed a partnership agreement with Beijing Aosaikang Pharmaceutical (Shenzhen Stock Exchange stock code: 002755), announcing an exclusive collaboration on the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted drug, Eluthera Elysonib (Oyi Cheng).
No Data
No Data